0002078856 EX-FILING FEES 0002078856 2025-09-04 2025-09-04 0002078856 1 2025-09-04 2025-09-04 0002078856 2 2025-09-04 2025-09-04 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

Exhibit 107

 

Calculation of Filing Fee Tables

Form S-4

(Form Type)

 

Hyperliquid Strategies Inc

(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered and Carry Forward Securities

 

   Security
Type
 
  Security
Class
Title
  Fee
Calculation
or Carry
Forward
Rule
   Amount
Registered
   Proposed
Maximum
Offering
Price Per
Unit
   Maximum
Aggregate
Offering Price
  

Fee

Rate

  

Amount of
Registration

Fee

  

Carry

Forward

Form

Type

   Carry
Forward
File
Number
  

Carry

Forward

Initial

Effective

Date

   Filing Fee
Previously
Paid In
Connection
with
Unsold
Securities
to be
Carried
Forward
 
Newly Registered Securities  
Fees to Be Paid  Equity  Common Stock   457(c), 457(f)(1)    322,129,655(1)   3.18   $1,024,372,302.92(3)   0.0001531   $156,831.40(5)                                                  
   Equity  Common Stock   457(c), 457(f)(2)    466,612,008(2)   0.000033   $15,398.20(4)   0.0001531   $2.36(5)                    
Carry Forward Securities  
Carry Forward Securities  -  -   -    -         -              -    -    -    - 
   Total Offering Amounts        $1,024,387,701.12        $156,833.76                     
   Total Fees Previously Paid                  $0                     
   Total Fee Offsets                  $0                     
   Net Fee Due                  $156,833.76                     

 

  (1) Represents the maximum number of shares of common stock of Hyperliquid Strategies Inc (“Pubco”) issuable to holders of common stock of Sonnet BioTherapeutics Holdings, Inc. (“Sonnet”), including holders of securities that may be exercised for or settled into shares of Sonnet’s common stock (collectively, “Sonnet Equity Holders”), upon the completion of the transactions described in this registration statement based on (i) 6,827,352 issued and outstanding shares of Sonnet’s common stock, (ii) 15,160,028 shares of Sonnet’s common stock issuable upon the exercise of outstanding warrants to purchase shares of Sonnet’s common stock, (iii) 243,787,992 shares of Sonnet’s common stock issuable to investors pursuant to certain subscription agreements, (iv) 10,911,200 shares of Sonnet’s common stock issuable to Chardan Capital Markets LLC as consideration to its service as an advisor to the proposed business combination, (v) 6,000,000 shares of Sonnet’s common stock issuable to certain initial PIPE subscribers, and (vi) 39,443,083 shares of Sonnet’s common stock issuable to Rorschach Advisors LLC.
  (2) Represents the maximum number of shares of common stock of Pubco (“Pubco Common Stock”) issuable to holders of membership interests of Rorschach I LLC (“Rorschach”), including holders of securities that may be exercised for or settled into Rorschach’s membership interests (collectively, “Rorschach Equity Holders”), upon the completion of the transactions described in this registration statement based on 466,612,008 shares of Pubco Common Stock issuable to investors pursuant to certain contribution agreements.
  (3) Estimated solely for purposes of calculating the amount of the registration fee and computed pursuant to Rules 457(c) and 457(f)(1) promulgated under the Securities Act of 1933, as amended (the “Securities Act”). Such amount equals the product of (x) $3.18, the average of the high and the low prices of shares of Sonnet’s common stock, as reported on the Nasdaq Capital Markets LLC on September 2, 2025, and (y) 322,129,655, the maximum number of shares of Pubco common stock issuable to Sonnet Equity Holders upon the completion of the transactions, as described in footnote 1 above.
  (4) Estimated solely for purposes of calculating the registration fee in accordance with Rule 457(f)(2) of the Securities Act based upon an amount equal to one-third of the par value of the shares of common stock to be exchanged in the Business Combination as of immediately prior to the consummation of the Business Combination. Rorschach is a private company, no market exists for its securities and Rorschach has an accumulated capital deficit.
  (5) Calculated pursuant to Rule 457(f) of the Securities Act by multiplying the proposed maximum aggregate offering price by 0.0001531.

N/A